News Contact Us Careers Get E-Mail alerts Search

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Yes No

News

See below for our most recent and archived news events.

Click below for current and archived news related to the company.

ADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections

Mar 03, 2020 7:00am EST

ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock

Feb 24, 2020 7:00am EST

ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™

Feb 11, 2020 4:20pm EST

ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock

Feb 06, 2020 8:40pm EST

ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock

Feb 06, 2020 4:06pm EST

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook

Jan 09, 2020 7:00am EST

ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions

Jan 07, 2020 7:00am EST

ADMA Biologics Added to NASDAQ Biotechnology Index

Dec 17, 2019 7:08am EST

ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference

Nov 13, 2019 7:08am EST

ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress

Nov 06, 2019 5:02pm EST

1
2
3
4
5
6
7
8
9
10
...20